[go: up one dir, main page]

ZA853504B - Pyridazinones,preparation process thereof and utilization thereof,drugs containing pyridazinones - Google Patents

Pyridazinones,preparation process thereof and utilization thereof,drugs containing pyridazinones

Info

Publication number
ZA853504B
ZA853504B ZA853504A ZA853504A ZA853504B ZA 853504 B ZA853504 B ZA 853504B ZA 853504 A ZA853504 A ZA 853504A ZA 853504 A ZA853504 A ZA 853504A ZA 853504 B ZA853504 B ZA 853504B
Authority
ZA
South Africa
Prior art keywords
pyridazinones
utilization
preparation process
drugs containing
alkoxy
Prior art date
Application number
ZA853504A
Other languages
English (en)
Inventor
Hermann Amschler
Klaus Eistetter
Manfred Eltze
Dieter Flockerzi
Ulrich Kilian
Norbert Kolassa
Karl Sanders
Wolf-Ruediger Ulrich
Original Assignee
Byk Gulden Lomberg Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chem Fab filed Critical Byk Gulden Lomberg Chem Fab
Publication of ZA853504B publication Critical patent/ZA853504B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA853504A 1984-05-10 1985-05-09 Pyridazinones,preparation process thereof and utilization thereof,drugs containing pyridazinones ZA853504B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH229784 1984-05-10

Publications (1)

Publication Number Publication Date
ZA853504B true ZA853504B (en) 1985-12-24

Family

ID=4230485

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA853504A ZA853504B (en) 1984-05-10 1985-05-09 Pyridazinones,preparation process thereof and utilization thereof,drugs containing pyridazinones

Country Status (15)

Country Link
US (1) US4665074A (xx)
EP (1) EP0163965B1 (xx)
JP (1) JPH062750B2 (xx)
AT (1) ATE47844T1 (xx)
AU (1) AU578947B2 (xx)
CA (1) CA1245651A (xx)
DE (1) DE3574137D1 (xx)
DK (1) DK159431C (xx)
ES (1) ES8607950A1 (xx)
GR (1) GR851039B (xx)
IE (1) IE58033B1 (xx)
IL (1) IL75070A (xx)
NZ (1) NZ211995A (xx)
PT (1) PT80426B (xx)
ZA (1) ZA853504B (xx)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU640137B2 (en) * 1989-04-17 1993-08-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel arylpyridazines, their manufacture, use and medicaments containing them
ATE168101T1 (de) * 1990-10-16 1998-07-15 Byk Gulden Lomberg Chem Fab Arylpyridazinone
WO1992019602A1 (de) * 1991-04-26 1992-11-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue pyridazine
JPH06508842A (ja) 1991-07-05 1994-10-06 ビイク　グルデン　ロンベルク　ヒエーミツシエ　フアブリーク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング 置換ピリダジンの皮膚病に対する使用
DE122010000043I1 (de) * 1993-07-02 2011-01-27 Nycomed Gmbh Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
SI0988302T1 (en) 1997-06-03 2003-08-31 Altana Pharma Ag Benzonaphthyridines
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
HU229439B1 (hu) 1999-08-21 2013-12-30 Takeda Gmbh Roflumilast és salmeterol szinergetikus kombinációja
KR20040007596A (ko) 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 골절 치료 촉진용 조성물
ES2427930T3 (es) 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos
NZ545787A (en) * 2001-10-01 2007-12-21 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004226353A1 (en) 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
ATE490788T1 (de) 2003-04-25 2010-12-15 Gilead Sciences Inc Antivirale phosphonate analoge
US7432261B2 (en) * 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
CA2522845A1 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
WO2005044308A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
EP1778251B1 (en) 2004-07-27 2011-04-13 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
EP2266994B1 (en) * 2004-08-02 2013-04-03 University Of Virginia Patent Foundation 2-propynyl adenosine analgos with modified 5'-ribose groups having A2A agonist activity
WO2006028618A1 (en) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006023272A1 (en) * 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
ES2393962T3 (es) * 2008-07-08 2013-01-03 Gilead Sciences, Inc. Sales de compuestos inhibidores del VIH.
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
FR3027901B1 (fr) * 2014-10-31 2018-03-16 Universite De Reims Champagne Ardenne Nouveaux procedes appartenant a la famille des pyridazinones.
PT3661937T (pt) 2017-08-01 2021-09-24 Gilead Sciences Inc Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2435244A1 (de) * 1974-07-22 1976-02-05 Lentia Gmbh Verfahren zur herstellung von 3-phenylpyridazonen
DE2445681A1 (de) * 1974-09-25 1976-04-15 Lentia Gmbh Verfahren zur herstellung von 3-phenylpyridazonen
JPS6037101B2 (ja) * 1977-03-09 1985-08-24 三共株式会社 フエニルピリダジノン誘導体の製法
DE2757923A1 (de) * 1977-12-24 1979-06-28 Hoechst Ag Verfahren zur herstellung von 3-pyridazonen
US4397854A (en) * 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
IT1173591B (it) * 1983-05-11 1987-06-24 Byk Gulden Lomberg Chem Fab Piridazioni,loro preparazione e impiego,farmaci contenenti piridazioni
PT78566B (de) * 1983-05-11 1986-07-17 Byk Gulden Lomberg Chem Fab Pyridazinone ihre herstellung und verwendung pyridazinone enthaltende arzneimittel

Also Published As

Publication number Publication date
JPH062750B2 (ja) 1994-01-12
ATE47844T1 (de) 1989-11-15
GR851039B (xx) 1985-05-28
JPS60246375A (ja) 1985-12-06
IE58033B1 (en) 1993-06-16
DK177585D0 (da) 1985-04-19
EP0163965A3 (en) 1987-06-24
DK159431B (da) 1990-10-15
AU4177585A (en) 1985-11-14
AU578947B2 (en) 1988-11-10
EP0163965B1 (de) 1989-11-08
ES8607950A1 (es) 1986-06-16
IE851146L (en) 1985-11-10
IL75070A (en) 1988-11-15
IL75070A0 (en) 1985-09-29
DE3574137D1 (en) 1989-12-14
DK177585A (da) 1985-11-11
PT80426A (de) 1985-06-01
ES542979A0 (es) 1986-06-16
EP0163965A2 (de) 1985-12-11
CA1245651A (en) 1988-11-29
PT80426B (de) 1987-04-16
US4665074A (en) 1987-05-12
DK159431C (da) 1991-03-18
NZ211995A (en) 1987-11-27

Similar Documents

Publication Publication Date Title
ZA853504B (en) Pyridazinones,preparation process thereof and utilization thereof,drugs containing pyridazinones
ES8703876A1 (es) Un procedimiento para la preparacion de derivados de purina.
ES8701733A1 (es) Procedimiento para detectar peroxido de hidrogeno o sustancias formadoras de peroxido de hidrogeno
ES8203883A1 (es) Un procedimiento para la preparacion de derivados de imida- zol
ES8702371A1 (es) Un procedimiento para preparar nuevos derivados de 6-(4-fenilo sustituido -3(2h) piradazinona.
ES2004386A6 (es) Un procedimiento para producir un nuevo derivado de difluorohalometoxifenilo
DE3462890D1 (en) Pyridazinones, their preparation and use, medicines containing these pyridazinones
ES8800156A1 (es) Procedimiento para preparar nuevos derivados 3-piridilmetilnaftilicos
DE3374005D1 (en) 1-methyl-5-nitro-imidazoline derivatives and therapeutic compositions which contain them as active principle
ES8301209A1 (es) Un procedimiento para la preparacion de derivados de pirro- lidina
ES8507472A1 (es) Procedimiento de preparar compuestos tratamiento de la hipertension
ES8500619A1 (es) Procedimiento de preparacion de derivados de eburnano-oxima racemicos u opticamente activos.
ES8606272A1 (es) Procedimiento para preparar derivados carboxialquildipepti- dicos
ES8106156A1 (es) Un procedimiento para la preparacion de derivados de oxadia-zolotriazona
ES8103047A1 (es) Procedimiento de preparacion de derivados aminoisoquinolinosasi como de sus sales de adicion acidas, farmaceuticamente aceptables y de sus derivados amonicos cuaternarios
AU579997B2 (en) Iminosulphonamides and processes for the manufacture thereof, pharmaceutical preparations containing such compounds, and their use
CA2012661A1 (en) Thienylpiperazines, process for the Preparation Thereof, the Use Thereof, and Pharmaceuticals Containing These and the Preparation Thereof
ES8504193A1 (es) Un procedimiento de preparacion de hexahidro-indolo-naftiridinas
MY102050A (en) Imidazole anologs of mevalonolactone and derivatives thereof
ES8706653A1 (es) Un procedimiento para la preparacion depropionilamilidas